PMID: 8595621Nov 1, 1995Paper

Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats

Cardiovascular Research
R MathewM H Gewitz

Abstract

Nitric oxide (NO) and endothelin-1 (ET-1) have both been implicated in the pathogenesis of pulmonary hypertension (PH). Therefore, we examined NO-related relaxation and ET-1 levels in rat hilar pulmonary arteries (PA) during the progression of monocrotaline (MCT)-induced PH. Rats were studied 1 and 2 weeks after a single subcutaneous injection of MCT (80 mg/kg). Pulmonary artery pressure (PAP), right ventricular hypertrophy (RVH), NO-related relaxation and tissue ET-1 levels in PA were evaluated and compared with control (C). One week post-MCT, endothelium (E)-dependent relaxation to 10(-5) M adenosine diphosphate (ADP), 10(-5) M A23187 and 10(-5) M acetylcholine (ACh) and tissue ET-1 levels in PA were normal. Rats in this group did not develop PH or RVH. Two weeks post-MCT, E-dependent relaxation was impaired (ADP, 7 +/- 3% VS. c, 62 +/- 5%; A23187, 2 +/- 7% vs. C, 58 +/- 2%; ACh, 33 +/- 7% vs. C, 86 +/- 2%; P < 0.05) and ET-1 levels were elevated (1925 +/- 244 pg/g wwt vs. C, 469 +/- 59 pg/g wwt, P < 0.05), In addition, significant PH and RVH were present (PAP 33 +/- 4 mmHg vs. C 18 +/- 0.8 mmHg, P < 0.05; RVH index 0.40 +/- 0.006 vs. C, 0.25 +/- 0.01, P < 0.05). Incubation with 10 microM indomethacin, 150 U/ml superoxide dis...Continue Reading

Citations

Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Toshihiko NishimuraPeter N Kao
Dec 4, 2002·Environmental Health Perspectives·Joao R F BatalhaJohn J Godleski
Jul 15, 2009·Hypertension·Anna CsiszarZoltan Ungvari
Jun 11, 2011·Pulmonary Medicine·Rajamma Mathew
Sep 1, 2005·Toxicology and Applied Pharmacology·Wei ChengYushi Ito
Jun 28, 2000·Journal of the Autonomic Nervous System·P M Vanhoutte
Nov 27, 2015·Pulmonary Pharmacology & Therapeutics·Poorella LingeshwarKashif Hanif
Apr 24, 2008·Clinical and Experimental Pharmacology & Physiology·Maristela P Souza-RabboAdriane Belló-Klein
Apr 22, 2010·Italian Journal of Pediatrics·Nagla T El-Melegy, Nagwa A Mohamed
Mar 15, 2011·Cell Transplantation·Philipp JungebluthPaolo Macchiarini
Jan 25, 2006·Respiration; International Review of Thoracic Diseases·Noriyuki HommaYoshinosuke Fukuchi
Apr 18, 2007·Cardiology in Review·Rajamma MathewMichael H Gewitz
Sep 19, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Syed R BaberPhilip J Kadowitz
Oct 8, 1999·Anesthesia and Analgesia·D J HorstmanG F Rich
Aug 21, 2013·Journal of Synchrotron Radiation·Emily A GrayDaryl O Schwenke
Oct 29, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Rajamma Mathew
Feb 10, 1998·Journal of Cardiovascular Pharmacology·L BrownC Sernia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.